2 results
Search Results
Now showing 1 - 2 of 2
Article Citation - WoS: 4Citation - Scopus: 7Evaluation of Perylenediimide Derivatives for Potential Therapeutic Benefits on Cancer Chemotherapy(Wiley, 2012) Keskin, Taner; Isgor, Belgin S.; Isgor, Yasemin G.; Yukruk, FundaPerylene derivatives, known to have potential therapeutic benefits on particular cancer types as photosensitizers, may also function as small-molecule inhibitors with promising therapeutic value for diverse diseases. This recently recognized biological activity was attributed to their capacity to modulate the function of various enzymes as biological targets in vitro. Although the inhibitory activity on glutathione transferase and Src tyrosine kinase is important in determining the anticancer potential of compounds for target-specific drug design and development, to date, there are no successful inhibitors of this kind. Moreover, there are only a few studies about the effects of perylene derivatives on glutathione transferase and various kinases. In this study, four novel perylene compounds, N,N'-disubstituted perylenediimides and their 1,7-dibromo derivatives, were synthesized and evaluated for their biological activities. Here, among the compounds analyzed, one of them was identified with strong glutathione transferase inhibition and two with dual activity for both glutathione transferase and c-src inhibition. These results revealed that perylene derivatives may be employed as potential chemosensitizers to prevent chemotherapy-dependent drug resistance and identified as prospective anticancer agents with dual activity on both glutathione transferase and c-src enzymes.Article Citation - WoS: 8Citation - Scopus: 9Effect of Alpha-1-Adrenoceptor Blocker on Cytosolic Enzyme Targets for Potential use in Cancer Chemotherapy(Asian Network Scientific information-ansinet, 2012) Isgor, Belgin S.; Isgor, Yasemin G.Doxazosin is one of the quinazoline-based alpha 1-adrenergic receptor antagonists in clinical use for the treatment of hypertension and benign prostate hyperplasia. Doxazosin-induced cytotoxicity studies, resulted in growth inhibition and apoptosis, show its potential therapeutic benefits for several forms of cancers. These effects on cells occur as adrenoceptor-independent mechanisms, as observed with other quinazoline family of alpha-1 blockers. Moreover, Doxazosin induced apoptosis is associated with pathways, including EGFR, NF-kappa beta and TGF-beta signaling which typically engage Src as a central signaling component. Recent evidences show that glutathione transferases, may also contribute to these signaling events, through the kinases that share signaling pathways with Src, responsible for the regulation of transferase activity. In addition, the overactive glutathione transferases are related with anticancer drug resistance, as well as cancer development. Therefore, in the present study, the anticancer potential of Doxazosin was investigated by in vitro enzyme assays that were used to develop full dose-response profiles of drug at varying doses. The drug dose that exerts 50% inhibition of enzyme activity is defined as IC50 value and determined through the nonlinear regression analysis of dose-response data. The IC50 values determined for Src kinase, total protein tyrosine kinase, cytosolic total Src family kinase and total glutathione transferase enzymes were within nanomolar to low micromolar range. These results suggest that Doxazosin may be used to improve multifunctional therapeutic formulations to provide reduced drug resistance and enhanced cytotoxicity at target tissues.
